Amtolmetin guacyl versus piroxicam in patients with osteoarthritis

Journal of International Medical Research

Volumn 28, Issue 2, 2000, Pages 91-100

  Montrone, F ^a   Santandrea, S ^a   Caruso, I ^a   Gerli, R ^b   Cesarotti, M E F ^b   Frediani, P V ^c   Bassani, R ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c Azienda Ospedaliera S Antonio Abate di Gallarate   (Italy)

Author keywords

Amtolmetin guacyl; Gastrointestinal tolerability; Non steroidal anti inflammatory drug; Osteoarthrosis; Perforation; Piroxicam; Ulcer and bleeding

Indexed keywords

ANTOLMETIN GUACYL; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OSTEOARTHRITIS; RANDOMIZED CONTROLLED TRIAL;

EID: 0034095623     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000002800204     Document Type: Article

References (29)

1. Lawrance JS, Bremner JM, Bier F: Osteoarthrosis prevalence in the population and relationship between symptoms and X-ray changes. Ann Rheum Dis 1966; 25: 1-24.
2. Silman A, Hochberg MC (eds): Epidemiology of the Rheumatic Diseases. Oxford: Oxford University Press, 1993.
3. Liang MH, Larson M, Thompson M, et al: Costs and outcomes in rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1984; 27: 522-529.
4. Moralestorres J, Reginister JC, Hochberg MC: Rheumatic and muscoloskeletal diseases and impaired quality of life: a challenge for rheumatologists. J Rheumatol 1996; 23: 1-3.
5. Caruso I, Bianchi Porro G: Gastroscopic evaluation of anti-inflammatory drugs. Br Med J 1980; 1: 75-78.
6. Wallace JL: Nonsteroidal antiinflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997; 112: 1000-1016.
7. Montrone F, Petrillo M, Caruso I, et al: A comparison of severe gastric damage as a result of pirprofen and naproxen treatment in rheumatoid arthritis: a controlled endoscopic study. J Intern Med 1994; 236: 153-159.
8. Fries JF: NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991; 18: 6-10.
9. Gabriel SE: Non-steroidal anti-inflammatory drugs and gastrointestinal disease: is there a better approach to NSAID use? Ital J Gastroenterol Hepatol 1998; 30: 146-150.
10. Smalley WE, Griffin MR: The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol Clin North Am 1996; 25: 373-396.
11. Levine JS: Misoprostol and nonsteroidal anti-inflammatory drugs: a tale of effects, outcomes and costs. Ann Intern Med 1995; 123: 309-310.
12. Stucki G, Johannesson M, Liang MH: Is misoprostol cost-effective in the prevention of nonsteroidal anti-inflammatory drug-induced gastropathy in patients with chronic arthritis? A review of conflicting economic evaluations. Arch Intern Med 1994; 154: 2020-2025.
13. Petazzi I, Corberi G, Bonollo L, et al: Cinical study of the therapeutic activity and tolerability of Artromed in comparison with Piroxicam in rheumatoid arthritic patients. Drugs Exp Clin Res 1990; XVI(suppl): 31-37.
14. Ghirardini M, Betelemme L, Fatti F, et al: Evaluation of the gastric tolerability of ST 679 in comparison with indomethacin: double-blind study in healthy volunteers. Drugs Exp Clin Res 1990 XVI(suppl): 19-24.
15. Tubaro E, Belogi L, Mezzadri CM, et al: Studies on the gastric tolerability of the new non-steroidal anti-inflammatory drug amtolmetin guacil. Arzneimforsch/Drug Res 1995; 45: 1298-1302.
16. Coruzzi G, Bertaccini G: Gastric effects of the novel nonsteroidal anti-inflammatory drug: amtolmetin guacil. Nutrition 1999; 15: 325-326.
17. Pisano C, Grandi D, Morini G, et al: Gastrosparing effect of a new anti-inflammatory drug amtolmetin guacyl in the rat: involvement of nitric oxide. Dig Dis Sci 1999; 44: 713-724.
18. Bianchi Porro G, Montrone F, Lazzaroni M: Clinical and gastroscopic evaluation of amtolmetin guacyl versus diclofenac in patients with rheumatoid arthritis. Ital J Gastroenterol Hepatol 1999; 31: 378-385.
19. Brogden RN, Heel LC, Speight TM, et al: Piroxicam. A reappraisal of its pharmacology and therapeutic efficacy. Drugs 1984; 28: 292-323.
20. Towheed TE, Hochberg MC: A systemic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the knee, with an emphasis on trial methodology. Sem Arthritis Rheum 1997; 26: 755-770.
21. Gabriel SE, Jaakkimainen RL, Bombardier C: Risk of serious gastrointestinal complication, related to use of non steroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115: 787-796.
22. Silverstein FE, Graham DY, Senior JR, et al: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs. Ann Intern Med 1995; 123: 241-249.
23. Hawkey C, Kahan A, Steinbruck K, et al: Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatol 1998; 37: 937-945.
24. Singh G, Ramey DR, Balise R, et al: Epidemiology of NSAID related GI complications in patients with osteoarthritis (OA): a 13 years prospective study (abstract). Arthritis Rheum 1998; 41: 5180.
25. Vane J: Towards a better aspirin. Nature 1994; 367: 215-216.
26. Jacob M, Simpson R, Bjarnason I: Non steroidal anti-inflammatory drugs, cyclooxygenase selectivity and gastrointestinal toxicity. Ital J Gastroenterol Hepatol 1998; 30: 12-18.
27. Brogden RN, Heel RC, Speight TM: Tolmetin: a review of its pharmacological properties and therapeutic efficacy in rheumatic diseases. Drugs 1978; 15: 429-450.
28. Donnelly MT, Courtauld EM, Galrlick N, et al: Nitric oxide donating flurbiprofen (HCT 1026) causes less endoscopic damage in healthy volunteers than flurbiprofen (abstract). Gastroenterology 1999; 114: A107.
29. Wallace JL, Reuter BK, Cirino G: Nitric oxide-releasing non steroidal anti-inflammatory drugs: a novel approach for reducing gastrointestinal toxicity. J Gastroenterol Hepatol 1994; 1: 40-45.